Scarica l'app Stockscreener
8.17
3.55%
0.28
Dopo l'orario di chiusura:
8.16
-0.010
-0.12%
Precedente Chiudi:
$7.89
Aprire:
$7.99
Volume 24 ore:
617.27K
Relative Volume:
1.96
Capitalizzazione di mercato:
$197.92M
Reddito:
$68.38M
Utile/perdita netta:
$-20.17M
Rapporto P/E:
-9.2431
EPS:
-0.8839
Flusso di cassa netto:
$-14.13M
1 W Prestazione:
-6.31%
1M Prestazione:
+8.79%
6M Prestazione:
+166.99%
1 anno Prestazione:
-24.98%
Intervallo 1D:
$7.78
$8.20
Intervallo di 1 settimana:
$7.78
$8.69
Portata 52W:
$2.59
$12.23
Exagen Inc Stock (XGN) Company Profile
Nome
Exagen Inc
Settore
Industria
Telefono
(760) 560-1501
Indirizzo
1261 LIBERTY WAY, VISTA, CA
Compare XGN vs TMO, DHR, NTRA, A, IQV
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XGN
Exagen Inc
|
8.17 | 211.24M | 68.38M | -20.17M | -14.13M | -0.8839 |
TMO
Thermo Fisher Scientific Inc
|
654.80 | 249.58B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
214.06 | 157.81B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
410.35 | 59.47B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
167.78 | 48.71B | 7.23B | 1.41B | 1.09B | 4.979 |
IQV
Iqvia Holdings Inc
|
258.21 | 44.50B | 16.63B | 1.39B | 2.12B | 8.0674 |
Exagen Inc Stock (XGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-11 | Iniziato | B. Riley Securities | Buy |
| 2025-07-30 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2025-07-23 | Iniziato | Craig Hallum | Buy |
| 2022-08-05 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-04-15 | Iniziato | Canaccord Genuity | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-10-08 | Iniziato | BTIG Research | Buy |
| 2020-06-02 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-10-14 | Iniziato | Cowen | Outperform |
| 2019-10-14 | Iniziato | William Blair | Outperform |
Mostra tutto
Exagen Inc Borsa (XGN) Ultime notizie
Exagen Inc. (XGN) Stock Price & News - Syfe
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05% - Eastern Progress
Exagen (XGN) Receives a Buy from Roth MKM - The Globe and Mail
EXAGEN INC. Q1 REVENUE USD 17.306 MILLION VS. IBES ESTIMATE USD 16.4 MILLION - Moomoo
Exagen Inc.(NasdaqGM: XGN) dropped from S&P Global BMI Index - marketscreener.com
Exagen Stock Price Forecast. Should You Buy XGN? - StockInvest.us
Exagen Inc.Common Stock (NQ: XGN - The Chronicle-Journal
Exagen Q2FY26 Results: Revenue hits record $19.9 million, EBITDA nears breakeven - scanx.trade
Full Transcript: Exagen Q2 2026 Earnings Call - Benzinga
XGN Looks 113.8% Overvalued on GF Value™ - GuruFocus
B. Riley Securities Initiates Exagen(XGN.US) With Buy Rating, Announces Target Price $12 - Moomoo
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control ProgressEarnings Manipulation Risk - dars.gov.et
Have Insiders Sold Exagen Shares Recently? - simplywall.st
XGN Q2 2026 Earnings: Loss Narrows on Strong EPS BeatOne-Time Loss Impact - dars.gov.et
Tax-driven stock sale and ESPP buy for Exagen (XGN) CFO - Stock Titan
XGN Q2 2026 Earnings: Loss Narrows to -$0.13, Delivering 32.26% EPS Surprise, Yet Shares Ease 1.73%Performance Review - dars.gov.et
XGN | Exagen Inc. Common Stock FinancialsRevenue Breakdown - Quiver Quantitative
Exagen (XGN) director grant corrects prior option total - Stock Titan
Exagen (NASDAQ: XGN) grants director options at $4.31 strike - Stock Titan
Exagen (NASDAQ: XGN) grants Paul Kim 37,500 options at $4.31 - Stock Titan
Exagen Q2 2026 slides: record revenue, stock surges 36% By Investing.com - Investing.com Nigeria
Flputnam Investment Management Co. Takes $1.34 Million Position in Exagen Inc. $XGN - MarketBeat
GSA Capital Partners LLP Makes New Investment in Exagen Inc. $XGN - MarketBeat
XGN Q2 2026 Earnings: Narrower-Than-Expected Loss Lifts SentimentEarnings Acceleration Picks - vinanet.vn
XGN Q2 2026 Earnings: Narrower -$0.13 Loss Beats Estimates; Shares Slip 2.66%Retail Earnings Report - vinanet.vn
Exagen at Canaccord Genuity growth conference: turnaround gains pace - Investing.com
Metagenomi Therapeutics: Q2 Earnings Snapshot - AOL.com
Exagen Inc. (NASDAQ:XGN) Analysts Are Pretty Bullish On The Stock After Recent Results - webull.com
Agenus: Q2 Earnings Snapshot - aol.com
Exagen Inc. (XGN) Climbs 4.25% to $6.87, Holding Above Key SupportTPO Profile - dars.gov.et
Exagen (XGN) Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Rise 4.25%EPS Growth Report - dars.gov.et
Exzeo: Q2 Earnings Snapshot - AOL.com
Xenon Pharmaceuticals: Q2 Earnings Snapshot - AOL.com
Exagen Q2 2026 Earnings: Record Revenue and Reduced EBITDA Loss - sekbernews.id
Analysts Offer Insights on Healthcare Companies: Exagen (XGN), Amgen (AMGN) and Arvinas Holding Company (ARVN) - The Globe and Mail
Exagen (XGN) Stock Gets Fair Value Boost As Analysts Weigh Growth And Execution - Yahoo Finance
XGN Maintains Buy Rating -- Price Target Raised to $10.00 by TD Cowen - GuruFocus
XGN Reiterates by B. Riley Securities -- Price Target Raised to $12 - GuruFocus
Exagen Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:XGN) 2026-08-05 - Seeking Alpha
XGN Maintained by BTIG -- Price Target Raised to $9.00 - GuruFocus
Insiders At Exagen Sold US$680k Of Stock Potentially Indicating Weakness - Moomoo
B. Riley Adjusts Price Target on Exagen to $12 From $8, Maintains Buy Rating - marketscreener.com
BTIG Research Forecasts Strong Price Appreciation for Exagen (NASDAQ:XGN) Stock - MarketBeat
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Reve - GuruFocus
Exagen: The Path To Profitability Just Became More Credible (NASDAQ:XGN) - Seeking Alpha
TD Cowen Maintains Exagen(XGN.US) With Buy Rating, Raises Target Price to $10 - Moomoo
Exagen revenue reaches record level in Q2 2026 as test volume and ASP climb, lifts full year outlook - Traders Union
Exagen Inc. Stock 12‑Month Price Target Raised to $8.71, Implies 86% Upside - TradingView
Exagen Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Exagen Inc (XGN) (Q2 2026) Earnings Call Highlights: Record Revenue and Path to Profitability - Yahoo Finance
Exagen Q2 Earnings Call Highlights - Yahoo Finance
Exagen Inc Azioni (XGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exagen Inc Azioni (XGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ABALLI JOHN | President and CEO |
Mar 03 '26 |
Sale |
3.62 |
15,698 |
56,827 |
687,299 |
| ABALLI JOHN | President and CEO |
Feb 24 '26 |
Sale |
3.61 |
11,430 |
41,262 |
702,997 |
| Black Jeffrey G. | Chief Financial Officer |
Feb 24 '26 |
Sale |
3.61 |
1,584 |
5,718 |
267,442 |
| ABALLI JOHN | President and CEO |
Oct 16 '25 |
Sale |
11.82 |
31,787 |
375,598 |
714,427 |
0.97%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):